Balance Sheet
AssetsCash & Current InvestmentsCash & EquivalentsCurrent AssetsCurrent TaxesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLiabilities from Discontinued OperationsLong-Term InvestmentsNon-Current AssetsNon-Current DebtNon-Current Deferred Tax LiabilityOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPensionPrepaid AssetsProperty, Plant & Equipment (Net)Receivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Fresenius Medical Care AG (FMS) Cash & Equivalents (2016 - 2025)

Historic Cash & Equivalents for Fresenius Medical Care AG (FMS) over the last 17 years, with Q3 2025 value amounting to $1.4 billion.

  • Fresenius Medical Care AG's Cash & Equivalents fell 1159.19% to $1.4 billion in Q3 2025 from the same period last year, while for Sep 2025 it was $1.4 billion, marking a year-over-year decrease of 1159.19%. This contributed to the annual value of $1.3 billion for FY2024, which is 1645.54% down from last year.
  • Latest data reveals that Fresenius Medical Care AG reported Cash & Equivalents of $1.4 billion as of Q3 2025, which was down 1159.19% from $1.9 billion recorded in Q2 2025.
  • Fresenius Medical Care AG's 5-year Cash & Equivalents high stood at $1.9 billion for Q2 2025, and its period low was $1.2 billion during Q1 2025.
  • In the last 5 years, Fresenius Medical Care AG's Cash & Equivalents had a median value of $1.4 billion in 2023 and averaged $1.5 billion.
  • In the last 5 years, Fresenius Medical Care AG's Cash & Equivalents skyrocketed by 3144.32% in 2021 and then plummeted by 2332.74% in 2022.
  • Fresenius Medical Care AG's Cash & Equivalents (Quarter) stood at $1.7 billion in 2021, then decreased by 23.33% to $1.3 billion in 2022, then rose by 16.16% to $1.5 billion in 2023, then fell by 16.46% to $1.3 billion in 2024, then rose by 9.88% to $1.4 billion in 2025.
  • Its Cash & Equivalents was $1.4 billion in Q3 2025, compared to $1.9 billion in Q2 2025 and $1.2 billion in Q1 2025.